# reload+after+2024-01-22 21:44:07.964543
address1§80 Guest Street
address2§Suite 601
city§Boston
state§MA
zip§02135
country§United States
phone§617 500 8099
website§https://www.compasstherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§26
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Thomas J. Schuetz M.D., Ph.D.', 'age': 62, 'title': 'Co-Founder, CEO & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 829557, 'exercisedValue': 0, 'unexercisedValue': 376735}, {'maxAge': 1, 'name': 'Dr. Vered  Bisker-Leib M.D., MBA, Ph.D.', 'age': 52, 'title': 'President & COO', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 806433, 'exercisedValue': 0, 'unexercisedValue': 269821}, {'maxAge': 1, 'name': 'Mr. Neil L. Lerner CPA', 'age': 56, 'title': 'Vice President of Finance', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jonathan  Anderman J.D.', 'title': 'VP, Head of Legal & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Anna  Gifford', 'title': 'Communications Manager', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Minori  Rosales M.D., Ph.D.', 'age': 60, 'title': 'Senior VP & Head of Clinical Development', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karin  Herrera B.A.', 'title': 'VP & Head of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James  Kranz Ph.D.', 'title': 'VP and Head of Chemistry Manufacturing & Controls', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§9
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.399
currency§USD
dateShortInterest§1702598400
forwardEps§-0.44
exchange§NCM
quoteType§EQUITY
shortName§Compass Therapeutics, Inc.
longName§Compass Therapeutics, Inc.
firstTradeDateEpochUtc§1617629400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2da7fead-7fe9-351a-a396-4dd759234d3a
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§8.0
targetMeanPrice§9.17
targetMedianPrice§9.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§17.942
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
